Ligand Pharmaceuticals Inc
Latest Ligand Pharmaceuticals Inc News and Updates
Analysts’ Recommendations for United Therapeutics
In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.
Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders
Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.
Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst
Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.
Why Ligand Pharmaceuticals Tanked 25%
Today, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day.
Promacta and Jakavi May Boost Novartis’s Oncology Segment Revenues
Jakavi reported sales of $228.0 million in 4Q17, which is a year-over-year rise of 33.0% on a constant currency basis.
What Analysts Recommend for Alnylam Pharmaceuticals and Peers
On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.
What Analysts Recommend for Acadia Pharmaceuticals in September
Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”
Captisol-Enabled Prexasertib May Be Major Growth Driver for Ligand
Eli Lilly’s (LLY) Captisol-enabled drug Prexasertib is currently being evaluated in multiple oncology indications such as head and neck cancer, small-cell lung cancer (or SCLC), and advanced metastatic cancer.
Sparsentan May Be Solid Near-Term Growth Driver for Ligand
With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).
Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta
Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.
Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017
Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.
Technology Platforms and Research Programs Drive LGND’s Partnerships
Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.
Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals
Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.
Ligand Pharmaceuticals’ Shots-on-Goal Business Model
Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships.
Analysts’ Recommendations for Ligand Pharmaceuticals and Peers in 2017
In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.
How Did Keytruda Perform in 1Q17?
Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.
What Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016?
Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.
Agios Stock Rises on Higher Trading Volumes on June 8
Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.
Ionis Pharmaceuticals: Valuation Compared to Its Peers
In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.
Incyte Continues Its Growth Spree in 2015
Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.